Drug
Surufatinib And Tislelizumab Part 1
Surufatinib And Tislelizumab Part 1: highest development phase Phase 1/2, developed by Hutchmed. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Hutchmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Surufatinib and Tislelizumab _ Part 1 NCT04579757 | Phase 1/2 | Metastatic Solid Tumor |
Latest
No recent events.
Follow Surufatinib And Tislelizumab Part 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.